According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback